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Pyrano[3,4-b]pyrrol-7(1H)-one is a bicyclic structure that is rarely described in the literature but found 
in numerous polycyclic natural products as Lamellarins. This work presents an one-pot synthesis of 
pyrano[3,4-b]pyrrol-7(1H)-one substituted in 2- and 5-position. The reaction proceeds via a one-pot 
two steps 5-endo-dig and 6-endo-dig cyclizations catalyzed by a cationic gold complex with high 
regioselectivity 
 
Introduction  
Pyrano[3,4-b]pyrrol-7(1H)-one is a bicyclic structure found in many polyheterocyclic molecules and 
natural compounds as Ningalin B and Lamellarins (Figure 1). Ningalin B is a marine natural product, 
and its are potent multidrug resistance reversal agents of cancer cells.1 Pentacyclic Lamellarin D is one 
of the first example of Lamellarins alkaloids isolated from various marine organisms such as mollusks, 
sponges and ascidians.2,3 Since their discovery in 1985, about 50 new Lamellarins have been isolated 
and interest in these molecules has been growing due to their cytotoxicity and antitumor activity, 
multidrugs resistance reversal activity, HIV-1 integrase inhibition, and immunomodulatory activity.4 
Due to their various biological properties and the difficulty in obtaining large quantities of natural 
resources, many total syntheses of various Lamellarins have been published in the last decade.3,5 The 
preparation of analogs of these alkaloids has also been studied as an issue for pharmaco-modulating 
the Lamellarin core6 and for designing structures that are easier to access. Thus, diversely substituted 
molecules with tricyclic chromeno[3,4-b]-pyrrol-4(3H)-one7 and chromeno[3,4-b]-indol-6(7H)-one8 
scaffold were prepared. The latter showed inhibitory activities of DYRK1A kinase. However, the bicyclic 
pyrano[3,4-b]pyrrol-7(1H)-one is rarely described in the literature, and to the best of our knowledge, 
only few examples have been reported.9 Indeed, most recent works proposed an access to those 
structures starting from 1-methypyrrole-2-carboxylic acid, pyranone ring being formed by annulation 
with alkynes in presence of ruthenium or rhodium catalysts. 9b,c Herein, the development of a new 
synthetic pathway to access both pyrrole and pyranone cycles in a one-pot process is highly 
challenging. 
 
Figure 1. 
 
Over the past ten years, our group has been developing methodologies based on electrophilic or 
transition metal-catalyzed cyclization. We reported various approaches for the synthesis of biologically 
interesting heterocycles,10 such as tricyclic pyrano[3,4-b]indol-1(9H)-ones synthetized by a copper (I) 
catalyzed domino reaction.10d The strategy we envision here for the preparation of pyrano[3,4-
b]pyrrol-7(1H)-ones 3 is based on a double alkyne activation of diynes 2 (Figure 2), catalyzed by 
platinum11 or gold12 salts as known for their remarkable activation of alkynes.13 The compound 3 could 
be formed via heterocycle rings formed through 5-endo-dig and 6-endo-dig cyclization modes. The 
latter competes with the 5-exo mode—the regioselectivity is known to be dependent on the chain 
length, the substitution pattern on the chain, and the metal transition.14 The diynes 2 can be prepared 
via double Sonogashira cross coupling from β,β-dibromodehydroalanine derivatives 1 (Figure 2). 
 
Figure 2. Retrosynthetic pathways for the synthesis of pyrano[3,4-b]pyrrol-7(1H)-ones. 
 
Results and discussion 
First, β,β-dibromodehydroalanine derivatives 1 and 1’ were prepared according to procedures 
previously described in the literature15 (four steps from Serine (Scheme 1)). Compounds 2 were then 
prepared in average to good yields using a double Sonogashira cross coupling between compounds 1 
and various alkynes using a procedure modified from the literature.15c Derivative of compound 1 were 
prepared by replacing tert-butoxycarbonyl group by benzyloxycarbonyl group. Unfortunately, we did 
not succeed in carrying out the double Sonogashira coupling with such a protective group. Mono 
coupling debrominated product was obtained. 
 
Scheme 1. Synthesis of compounds 2. 
 
We investigated the use of platinum (II) and (IV) salts in toluene for the cyclization of compounds 2'a 
(Table 1, entries 1 and 2) and 2a (entries 3 and 4). In all cases, we observed only the sole nitrogen 
cyclization via 5-endo-dig pathway that leads to pyrroles 4'a and 4a with good yields. We then 
considered the use of gold (I) salts associated with silver salts in order to facilitate the formation of 
cationic gold. Compound 2'a in the presence of (triphenylphosphine)gold (I) chloride and silver 
tetrafluoroborate in dichloromethane at 50 °C, leads to pyrrole 4'a (entry 5). According to the 
conditions described by Asao et al., we used tert-butanol as an additive to promote the living of R1 
group of the ester and formation of the lactone ring.16 The addition of t-BuOH to the reaction mixture 
lead to a loss of reactivity (conversion = 50%) and an inseparable mixture of 3a and 4'a in proportions 
of 40:60 (entry 6). On the other hand, under the same conditions, substrate 2a will form the compound 
3a with no trace of formation of the pyrrole 4a in the crude product and in modest yield (52%; entry 
7). The pyrano[3,4-b] pyrrol-7(1H)-one structure of compound 3a was determined by NMR 
experiments (see SI-S15). We thus confirmed the regioselectivity of the 6-endo-dig cyclization between 
the alkyne and the ester. The cyclization product from 5-exo-dig cyclisation was never observed.The 
amounts of catalysts (entries 8) and the solvent (entries 8-10) are then optimized from 2a. The use of 
gold salts as catalysts and silver salts as co-catalysts are required. Indeed, there is no conversion 
without silver salts (entry 11). Without gold catalyst, the conversion is not complete, and a mixture of 
3a, 4'a, and a third indeterminate compound was obtained (entry 12). The products could not be 
separated. The use of silver triflate instead of silver tetrafluoroborate allows the formation of 3a in 
similar yields.  
We then prepared a series of bicyclic compounds with our method using gold catalysis (Table 2). The 
preparation of these compounds also appeared including aryls (entries 1-3 and 5) and alkyls (entries 6 
and 7) with yields of up to 82%. Here we also noted less efficient cyclization with electron-poor aryls 
(entry 3). This result can be explained by the fact that the position attacked on the alkyne moiety was 
less electrophilic due to the electron-poor substituent. The efficiency of gold was reduced by the amino 
substituted aryl. This resulted in the only example without closing of both cycles (entry 4). In this case, 
pyrrole 4d was the only product.  
 
 
 
 
 
 
 
 
 
Table 1. Optimization of reaction conditionsa 
 
Entry Substrat
e 
Catalysts  Additive Conditions 3b 4b 
1 2’a PtCl4, 5 mol% - Toluene, 
90°C,  
overnight 
- 4’a, 64 
% 
2 2’a PtCl2, 5 mol% - Toluene, 
90°C,  
overnight 
- 4’a, 84 
% 
3 2a PtCl2, 5 mol% - Toluene, 
90°C,  
overnight 
- 4a, 70 % 
4 2a PtCl2, 5 mol% - Toluene, 
75°C,  
overnight 
- 4a, 70 % 
5 2’a PPh3AuCl, 5 
mol%, 
AgBF4, 6 mol% 
- CH2Cl2, 50°C,  
24 h 
- 4’a, 52 
% 
6 2’a PPh3AuCl, 5 
mol%, 
AgBF4, 5 mol% 
t-BuOH 
(3 equiv.) 
Benzene, rt,  
overnight 
ndc ndc 
7 2a PPh3AuCl, 5 
mol%, 
AgBF4, 5 mol% 
t-BuOH 
(3 equiv.) 
Benzene, rt,  
overnight 
3a, 52 
% 
- 
8 2a PPh3AuCl, 10 
mol%, 
AgBF4, 10 mol% 
t-BuOH 
(3 equiv.) 
Benzene, rt,  
overnight 
3a, 72 
% 
- 
9 2a PPh3AuCl, 10 
mol%, 
AgBF4, 10 mol% 
t-BuOH 
(3 equiv.) 
Toluene, rt,  
overnight 
3a, 60 
% 
- 
10 2a PPh3AuCl, 10 
mol%, 
AgBF4, 10 mol% 
t-BuOH 
(3 equiv.) 
CH2Cl2, rt,  
overnight 
3a, 41 
% 
- 
11 2a PPh3AuCl, 5 
mol%, 
t-BuOH 
(3equiv.) 
Toluene, rt,  
overnight 
- - 
12 2a AgBF4, 10 mol% t-BuOH 
(3 equiv.) 
Benzene, rt,  
overnight 
ndc ndc 
a Reactions were typically performed with 0.5 mmol of substrate. b Isolated yield. c Inseparable 
mixture
Table 2. Synthesis of pyrano[3,4-b]pyrrol-7(1H)-ones 3.a 
 
 
Entry 
2 
Products Yield 
(%)b 
1 2a 
 
3a, 72% 
2 2b 
 
3b, 82% 
3 2c 
 
3c, 45% 
4 2d 
 
4d, 58% 
5 2e 
 
3e, 72% 
6 2f 
 
3f, 66% 
7 2g 
 
3g, 75% 
a Conditions: 2 (0.5 mmol), (Ph3P)AuCl (0.05 mmol), AgBF4 or AgOTf (0.05 mmol), t-BuOH (1.5 mmol), 
benzene (2 mL), rt, overnight. b Isolated yields.   
 
Of note, the synthesis of compounds 3 can be accomplished in a two steps sequences because 
platinum (II) chloride allowed selective pyrrole synthesis. Trisubstituted pyrroles 4 were synthesized 
from 2a in the presence of platinum (II) chloride in toluene at 75 °C (Scheme 2). These compounds, in 
the presence of gold (I) and silver (I) salts, led to the formation of pyrano[3,4-b]pyrrol-7(1H)-ones 3 
according to a 6-exo-dig cyclization. Note that the yields are lower than those obtained by the one-pot 
procedure (Table 2). 
 
 
Scheme 2. Synthesis of compounds 3 in two steps. 
 
 
According to our results and the literature, we propose a mechanism based on gold catalysis (Scheme 
3). First, silver (I) will make it possible to form cationic gold (I), which interacts with the π-system of 
the substrate to form intermediate A. The nucleophilic attack of the nitrogen then proceeds via 5-
endo-dig cyclization to form the vinylgold species B. The protodemetallation of B liberated the pyrrole 
compound and the gold catalyst, which can then interact with the second alkyne to form the 
intermediate C. The nucleophilic attack of oxygen, according to a 6-endo-dig cyclization, leads to 
organogold D, which liberates compound 3 and gold (I) catalyst by protodemetallation. 
 
 
Scheme 3. Proposed reaction mechanism. 
 
 
Conclusions 
In summary, we developed a gold-catalyzed synthesis of pyrano[3,4-b]pyrrol-7(1H)-one derivatives 
from benzyl β,β-diacetylenic dehydroalanine esters. The substrates can be easily prepared by 
Sonogashira coupling, and this reaction offers two-step and rapid access to various new pyrano-
pyrroles resulting from double intramolecular nucleophilic 5-endo and 6-endo-additions to a 
carbon˗carbon triple bond. We are currently evaluating these compounds for their biological effects. 
Moreover, studies to extend the scope of the synthetic utility of this one-pot reaction are underway in 
our laboratory.  
 
Experimental 
All reactions were carried out under argon atmosphere in dried glassware. Toluene and 
benzene were dried and freshly distilled from sodium. Acetonitrile was dried and freshly 
distilled from CaH2. (Ph3P)AuCl, AgOTf, AgBF4 and CuI were purchased from Sigma-Aldrich®, in 
≥99.9%, ≥99.95% and 98% purity respectively. (Ph3P)2PdCl2 was prepared from PdCl2 and PPh3. 
Reactions were monitored by TLC with Merck® Silica gel 60 F254. Purifications by flash 
chromatography were carried out using Merck® Geduran® Si 60 silica gel (40-63 µm). 1H NMR 
spectra were recorded on a Bruker® Avance 300 (300 MHz) NMR spectrometer, using CDCl3 as 
solvent. Data, reported using Me4Si (δH = 0.00 ppm) as internal reference, were as follows (in 
order): chemical shift (δ in ppm relative to Me4Si), multiplicity (s, d, t, q, m, br for singlet, 
doublet, triplet, quartet, multiplet, broad) and coupling constants (J in Hz). 13C NMR was 
recorded at 75 MHz on the same instrument, using the CDCl3 solvent peak at (δC = 77.16 ppm) 
as reference. 19F NMR was recorded at 282 MHz on the same instrument, using the CClF3 peak 
at (δF = 0.0 ppm) as internal reference. Mass spectra were obtained on a Hewlett Packard 
(engine 5988A) by direct inlet at 70eV. IR spectra were recorded on a Perkin-Elmer Spectrum 
One spectrophotometer. Melting points were uncorrected. 
 
Preparation of starting materials 
Compound 2’ was prepared by the reported procedure.15c 
Preparation of compounds 1, 2a-g is reported in the supporting information. 
 
General procedure for the synthesis of compounds (3) 
AgBF4 (10 mol%, 0.05 mmol, 10 mg) or AgOTf  (10 mol%, 0.05 mmol, 13 mg) was added to a solution 
of (Ph3P)AuCl (10 mol%, 0.05 mmol, 25 mg) in freshly distilled benzene (2 mL). After 2 minutes, 2 (0.5 
mml) was added, followed by t-BuOH (3 equiv., 1.5 mmol, 138 µL). The reaction was then stirred 
overnight at room temperature before it was filtered through a pad of celite with EtOAc. The filtrate 
was then washed with a saturated aqueous solution of NaHCO3, dried over MgSO4 and solvents were 
evaporated under vacuum. Residues were purified by flash chromatography on silica gel to give 
compounds 3. 
 
tert-Butyl-7-oxo-2,5-diphenylpyrano[3,4-b]pyrrole-1(7H)-carboxylate (3a): Eluant: PE/Et2O 80/20, 
yield = 72%; C24H21NO4; Rf (PE/AcOEt : 90/10) = 0.30 ; yellow solid; m.p.: 135-137 °C , IR (ATR): ν = 2979, 
2928, 1761, 1727, 1285, 1259, 1146, 1124, 690; 1H NMR (300 MHz, CDCl3): δ = 1.54 (s, 9H), 6.40 (s, 1H), 
6.97 (s, 1H), 7.26-7.51 (m, 8H), 7.84-7.87 (m, 2H) ; 13C NMR (75 MHz, CDCl3): δ = 27.3 (CH3), 86.4 (Cq), 
97.5 (CH), 106.5 (CH), 117.7 (Cq), 125.2 (CH), 128.5 (CH), 128.6 (CH), 128.8 (CH), 129.2 (CH), 129.5 (CH), 
131.1 (Cq), 132.4 (Cq), 134.4 (Cq), 144.6 (Cq), 148.4 (Cq), 153.9 (Cq), 154.6 (Cq) ; HRMS (ESI) calcd. for 
C24H22NO4 [M+H]+: 388.15433; found: 388.15441. 
 
tert-Butyl-2,5-bis(4-methoxyphenyl)-7-oxopyrano[3,4-b]pyrrole-1(7H)-carboxylate (3b): Eluant: 
PE/AcOEt 70/30, yield = 82%; C26H25NO6; Rf (PE/Et2O: 70/30) = 0.16 ; yellow solid; m.p.: 131-133 °C; IR 
(ATR): ν = 2941, 2842, 1748, 1724, 1608, 1291, 1249, 1025, 817; 1H NMR (300 MHz, CDCl3): δ = 1.57 (s, 
9H), 3.85 (s, 3H), 3.86 (s, 3H), 6.31 (s, 1H), 6.83 (s, 1H), 6.94-9.98 (m, 4H), 7.42 (m, 2H), 7.79 (m, 2H) ; 
13C NMR (75 MHz, CDCl3): δ = 27.5 (CH3), 55.49 (CH3), 55.52 (CH3), 86.3 (Cq), 96.0 (CH), 106.0 (CH), 
114.0 (CH), 114.3 (CH), 123.5 (Cq),125.3 (Cq), 126.8 (CH), 130.2 (CH), 135.0 (Cq), 144.8 (Cq), 148.7 (Cq), 
154.1 (Cq), 154.9 (Cq), 160.5 (Cq), 160.8 (Cq);  HRMS (ESI) calcd. for C26H26NO6 [M+H]+: 448.17546; 
found: 448.17540.   
 
tert-Butyl-2,5-bis(4-fluorophenyl)-7-oxopyrano[3,4-b]pyrrole-1(7H)-carboxylate (3c): Eluant: 
PE/AcOEt 80/20, yield = 45%; C24H19F2NO4; Rf (PE/Et2O: 80/20) = 0.27; yellow solid; m.p.: 138-140 °C IR 
(ATR): ν = 3078, 2985, 2933, 1762, 1731, 1291, 1156, 1141, 1125, 828; 1H NMR (300 MHz, CDCl3): δ = 
1.54 (s, 9H), 6.36 (s, 1H), 6.88 (s, 1H), 7.09-7.17 (m, 4H), 7.44-7.49 (m, 2H), 7.80-7.84 (m, 2H); 13C NMR 
(75 MHz, CDCl3): δ = 27.4 (CH3), 86.7 (Cq), 97.2 (CH), 106.7 (CH), 115.7 (d, 2JC-F = 21.9 Hz, CH), 116.0 (d, 
2JC-F = 22.0 Hz, CH), 117.6 (Cq), 127.2 (d, 4JC-F = 3.4 Hz, Cq), 127.3 (d, 3JC-F = 8.3 Hz, CH), 128.7 (d, 4JC-F = 
3.2 Hz, Cq), 130.8 (d, 3JC-F = 8.4 Hz, CH), 134.4 (Cq), 143.8 (Cq), 148.3 (Cq), 153.7 (Cq), 154.0 (Cq), 163.4 
(d, 1JC-F = 249.8 Hz, Cq), 163.6 (d, 1JC-F = 250.2 Hz, Cq) ; 19F NMR (282 MHz, CDCl3): δ = -111.9, -111.5; 
HRMS (ESI) calcd. for C24H20F2NO4 [M+H]+: 424.13549; found: 424.13553.  
 
tert-Butyl-2,5-bis(4-tert-butylphenyl)-7-oxopyrano-[3,4-b]pyrrole-1(7H)-carboxylate (3e): Eluant: 
PE/Et2O 95/5, yield = 72% ; C32H37NO4; Rf (PE/Et2O: 80/20) = 0.38; colorless oil; IR (ATR): ν = 2960, 2903, 
2870, 1765, 1728, 1477, 1285, 1148, 824; 1H NMR (300 MHz, CDCl3): δ = 1.34 (s, 9H), 1.35 (s, 9H), 1.55 
(s, 9H), 6.37 (s, 1H), 6.93 (s, 1H), 7.40-7.47 (m, 6H), 7.79 (m, 2H); 13C NMR (75 MHz, CDCl3): δ = 27.4 
(CH3), 31.29 (CH3), 31.34 (CH3), 34.8 (Cq), 86.2 (Cq), 96.9 (CH), 106.2 (CH), 117.5 (Cq), 125.0 (CH), 125.4 
(CH), 125.8 (CH), 128.2 (Cq), 128.4 (CH), 129.7 (Cq), 134.6 (Cq), 144.8 (Cq), 148.5 (Cq), 152.4 (Cq), 152.9 
(Cq), 154.1 (Cq), 154.8 (Cq); HRMS (ESI) calcd. for C32H38NO4 [M+H]+: 500.27954; found: 500.27966. 
 
tert-Butyl-2,5-dibutyl-7-oxopyrano[3,4-b]pyrrole-1(7H)-carboxylate (3f): Eluant: PE/Et2O 95/5; yield 
= 66%; C20H29NO4; Rf (PE/Et2O: 80/20) = 0.39; yellow oil; IR (ATR): ν = 2957, 2931, 2872, 1729 (br), 1305, 
1150, 840; 1H NMR (300 MHz, CDCl3): δ = 0.93 (m, 6H), 1.33-1.44 (m, 4H), 1.59-1.72 (m, 13H), 2.50 (t, J 
= 7.4 Hz, 2H), 2.84 (t, J = 7.4 Hz, 2H), 6.01 (s, 1H), 6.16 (s, 1H); 13C NMR (75 MHz, CDCl3): δ = 13.89 (CH3), 
13.95 (CH3), 22.2 (CH2), 22.5 (CH2), 27.6 (CH3), 27.7 (CH2), 29.4 (CH2), 31.0 (CH2), 33.3 (CH2), 85.6 (Cq), 
98.3 (CH), 104.6 (CH), 116.1 (Cq), 135.9 (Cq), 147.5 (Cq), 148.9 (Cq), 154.6 (Cq), 159.6 (Cq) ; HRMS (ESI) 
calcd. for C20H30NO4 [M+H]+: 348.21693; found: 348.21698.   
 
tert-Butyl-2,5-diisopentyl-7-oxopyrano[3,4-b]pyrrole-1(7H)-carboxylate (3g): Eluant: PE/Et2O 95/5, 
yield = 75%; C22H33NO4; Rf (PE/Et2O: 95/5) = 0.20; yellow oil; IR (ATR): ν = 2956, 2928, 2870, 1729 (br), 
1304, 1150, 841; 1H NMR (300 MHz, CDCl3): δ = 0.93 (app. t, J = 6.3 Hz, 12H), 1.50-1.61 (m, 6H), 1.65 
(s, 9H), 2.50 (t, J = 7.2 Hz, 2H), 2.84 (t, J = 7.5 Hz, 2H), 6.02 (s, 1H), 6.17 (s, 1H); 13C NMR (75 MHz, CDCl3): 
δ = 22.4 (CH3), 22.5 (CH3), 25.9 (CH2), 27.5 (CH3), 27.6 (CH), 27.9 (CH), 31.6 (CH2), 36.3 (CH2), 37.8 (CH2), 
85.6 (Cq), 98.2 (CH), 104.4 (CH), 116.1 (Cq), 135.8 (Cq), 147.7 (Cq), 148.8 (Cq), 154.5 (Cq), 159.8 (Cq); 
HRMS (ESI) calcd. for C22H34NO4 [M+H]+: 376.24824; found: 376.24749. 
 
General procedure for the synthesis of pyrroles (4) 
PtCl2 (5 mol%, 0.025 mmol, 6.6 mg) was added to a solution of 2 (0.5 mmol) in toluene (5 mL). Reaction 
mixture was stirred at 75 °C overnight, and then filtrated on a pad of celite with EtOAc. The filtrate was 
evaporated under vacuum, and the residues were purified by flash chromatography on silica gel to give 
compounds 4. 
 
1-(tert-Butyl) 2-methyl 5-phenyl-3-(phenylethynyl)-1H-pyrrole-1,2-dicarboxylate (4’a): Eluant: 
PE/AcOEt 95/5→80/20, yield = 64%; white solid; m.p.: 97-99 °C; C25H23NO4; Rf (PE/Et2O: 90/10) = 0.32; 
IR (ATR): ν = 3028, 2956, 1761, 1705, 1450, 1152, 760; 1H NMR (300 MHz, CDCl3): δ = 1.40 (s, 9H), 3.96 
(s, 3H), 6.38 (s, 1H), 7.32-7.36 (m, 3H), 7.38-7.46 (m, 5H), 7.52-7.57 (m, 2H); 13C NMR (75 MHz, CDCl3): 
δ = 27.3 (CH3), 52.0 (CH3), 82.9.0 (Cq), 85.9 (Cq), 93.5 (Cq), 113.0 (Cq), 114.2 (CH), 123.5 (Cq), 125.7 
(Cq), 128.3 (CH), 128.43 (CH), 128.45 (CH), 128.84 (CH), 129.1 (CH), 131.2 (Cq), 131.7 (Cq), 138.4 (Cq), 
148.9 (Cq), 160.5 (Cq). HRMS (ESI) calcd. for C25H24NO4 [M+H]+: 402.16998; found: 402.16917. 
 
2-Benzyl 1-tert-butyl 5-phenyl-3-(phenylethynyl)-1H-pyrrole-1,2-dicarboxylate (4a): Eluant: 
PE/AcOEt 95/5→90/10, yield = 70%; yellow oil; C31H27NO4; Rf (PE/Et2O: 90/10) = 0.22; IR (ATR): ν = 
3063, 3034, 2981, 2937, 1767, 1698, 1277, 1251, 1216, 1149, 1122, 1070, 752, 691; 1H NMR (300 MHz, 
CDCl3): δ = 1.37 (s, 9H), 5.39 (s, 2H), 6.38 (s, 1H), 7.23-7.30 (m, 8H), 7.38-7.50 (m, 7H); 13C NMR (75 
MHz, CDCl3): δ = 27.3 (CH3), 67.0 (CH2), 83.0 (Cq), 86.0 (Cq), 93.6 (Cq), 113.1 (Cq), 114.4 (CH), 123.4 
(Cq), 125.3 (Cq), 128.2 (CH), 128.28 (CH), 128.32 (CH), 128.4 (CH), 128.6 (CH), 128.8 (CH), 129.1 (CH), 
131.1 (Cq), 131.7 (Cq), 135.8 (Cq), 138.6 (Cq), 148.9 (Cq), 160.0 (Cq); HRMS (ESI) calcd. for C31H28NO4 
[M+H]+: 478.20128; found: 478.20191.  
 
2-Benzyl 1-tert-butyl 5-(4-methoxyphenyl)-3-((4-methoxyphenyl)-ethynyl)-1H-pyrrole-1,2-
dicarboxylate (4b): Eluant : PE/AcOEt 80/20, yield = 68%; beige solid; m.p.: 74-76°C; C33H31NO6; Rf 
(PE/AcOEt: 80/20) = 0.46; m.p.: 91-93°C; IR (ATR): ν = 2979, 2935, 2837, 2215, 1764, 1697, 1606, 1245; 
1H NMR (300 MHz, CDCl3): δ = 1.39 (s, 9H), 3.80 (s, 3H), 3.82 (s, 3H), 5.38 (s, 2H), 6.31 (s, 1H), 6.77 (m, 
2H), 6.92 (m, 2H), 7.16 (m, 2H), 7.24-7.29 (m, 3H), 7.36 (m, 2H), 7.49 (m, 2H); 13C NMR (75 MHz, CDCl3): 
δ = 27.3 (CH3), 55.38 (CH3), 55.43 (CH3), 66.8 (CH2), 81.8 (Cq), 85.8 (Cq), 93.7 (Cq), 113.6 (Cq), 113.7 
(CH), 113.9 (CH), 114.1 (CH), 115.6 (Cq), 123.4 (Cq), 124.7 (Cq), 128.1 (CH), 128.3 (CH), 128.6 (CH), 
130.5 (CH), 133.2 (CH), 135.9 (Cq), 138.7 (Cq), 149.2 (Cq), 159.6 (Cq), 160.1 (Cq); HRMS (ESI) calcd. for 
C33H32NO6 [M+H]+: 538.22241; found: 538.22246. 
 
2-Benzyl 1-tert-butyl 5-(4-(dimethylamino)phenyl)-3-((4-(dimethylamino)phenyl)ethynyl)-1H-
pyrrole-1,2-dicarboxylate (4d): Eluant: PE/AcOEt 50/50, yield = 36%; C35H37N3O4; Rf (PE/AcOEt : 50/50) 
= 0.61;  orange oil; IR (ATR): ν = 2978, 2888, 2802, 2208, 1762, 1695, 1606, 1149, 812; 1H NMR (300 
MHz, CDCl3): δ = 1.42 (s, 9H), 2.97 (s, 6H), 2.98 (s, 6H), 5.39 (s, 2H), 6.27 (s, 1H), 6.57 (m, 2H), 6.70 (m, 
2H), 7.15 (m, 2H), 7.25-7.33 (m, 5H), 7.51 (m, 2H); 13C NMR (75 MHz, CDCl3): δ = 27.4 (CH3), 40.4 (CH3), 
40.5 (CH3), 66.6 (CH2), 81.4 (Cq), 85.4 (Cq), 95.0 (Cq), 110.5 (Cq), 111.7 (CH), 111.8 (CH), 113.6 (CH), 
114.4 (Cq), 118.7 (Cq), 127.9 (CH), 128.2 (CH), 128.6 (CH), 130.0 (CH), 132.9 (CH), 136.2 (Cq), 139.8 
(Cq), 149.6 (Cq), 150.1 (Cq), 150.7 (Cq), 160.3 (Cq); HRMS (ESI) calcd. for C35H38N3O4 [M+H]+: 564.28568; 
found: 564.28601.  
 
2-Benzyl 1-tert-butyl 5-butyl-3-(hex-1-ynyl)-1H-pyrrole-1,2-dicarboxylate (4f): Eluant: PE/Et2O 95/5; 
yield = 48% ; C27H35NO4; Rf (PE/Et2O: 80/20) = 0.45; yellow oil; IR (ATR): ν = 2956, 2931, 2872, 2235, 
1755, 1704, 1226, 1158; 1H NMR (300 MHz, CDCl3): δ = 0.85-0.94 (m, 6H), 1.33-1.62 (m, 17H), 2.28 (t, 
J = 6.9 Hz, 2H), 2.67 (t, J = 7.2 Hz, 2H), 5.32 (s, 2H), 5.97 (s, 1H), 7.31-7.48 (m, 5H); 13C NMR (75 MHz, 
CDCl3): δ = 13.7 (CH3), 13.9 (CH3), 19.5 (CH2), 22.1 (CH2), 22.4 (CH2), 27.1 (CH2), 27.5 (CH3), 30.79 (CH2), 
30.84 (CH2), 66.5 (CH2), 73.9 (Cq), 85.2 (Cq), 95.1 (Cq), 112.8 (CH), 114.6 (Cq), 125.0 (Cq), 128.0 (CH), 
128.2 (CH), 128.5 (CH), 136.2 (Cq), 140.6 (Cq), 149.2 (Cq), 160.3 (Cq); HRMS (ESI) calcd. for C27H36NO4 
[M+H]+: 438.26389; found: 438.26384. 
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